How to Register a Patent in India 2026: Process, Timeline, Costs & Common Objections

Executive Summary

Patent registration india 2026 remains one of the most technically intricate procedures in intellectual property law, governed by a multi-stage statutory process that typically spans three to seven years from filing to grant. The Patents Act 1970, as substantially amended by the Patents (Amendment) Act 2005 and further refined through successive rules revisions culminating in the Patents (Amendment) Rules 2024, constitutes the primary legislative framework. The Office of the Controller General of Patents, Designs & Trade Marks (CGPDTM), headquartered in Kolkata with branch offices in Mumbai, Chennai, Delhi, and Ahmedabad, administers the entire lifecycle of a patent application in India. This article provides a comprehensive, jurisdiction-specific analysis of the patent registration process in India, explaining the filing routes available to applicants, the key procedural stages from filing of a patent application to grant, the applicable statutory fee schedule, and effective strategies to address common objections raised under Section 15 of the Patents Act, 1970.

Statutory Framework

The Patents Act 1970 and Its Amendments

The Patents Act 1970 (hereinafter “the Act”) is the foundational statute governing patentable subject matter, the rights conferred upon patentees, and the procedural architecture of patent prosecution in India. The Act defines a “patent” under Section 2(1)(m) as a patent for any invention granted under the Act. The definition of “invention” under Section 2(1)(j) requires that the subject matter be a new product or process involving an inventive step and capable of industrial application.

Section 3 of the Act enumerates inventions that are not patentable in India. This provision is broader than the exclusions found in many other jurisdictions. Section 3(d) in particular has attracted significant judicial and academic attention: it prohibits the grant of a patent for the mere discovery of a new form of a known substance that does not result in the enhancement of the known efficacy of that substance, or the mere discovery of any new property or new use for a known substance, or the mere use of a known process, machine, or apparatus unless such process results in a new product or employs at least one new reactant. Section 3(k) excludes mathematical or business methods, computer programmes per se, and algorithms from patentability. Section 3(p) excludes traditional knowledge or an aggregation or duplication of known properties of traditionally known components.

Section 6 specifies who may apply for a patent: the true and first inventor, an assignee of the right to make the application, or the legal representative of a deceased person who would have been entitled to apply. The term of a patent under Section 53 is twenty years from the date of filing of the application, subject to payment of renewal fees.

Patentable Subject Matter and Inventive Step

The three-pronged test for patentability requires novelty (Section 2(1)(l)), inventive step (Section 2(1)(ja)), and industrial applicability (Section 2(1)(ac)). The inventive step definition under Section 2(1)(ja) was inserted by the 2005 amendment and requires that the feature of an invention involves technical advance as compared to existing knowledge, or has economic significance, or both, and that the invention is not obvious to a person skilled in the art.

The Patents Rules 2003 and 2024 Amendments

The Patents Rules 2003, as amended most recently in 2024, govern procedural timelines, fee structures, and form requirements. The 2024 amendments introduced meaningful changes to examination timelines and fee revisions for natural persons, startups, and small entities to reduce financial barriers. The rules distinguish between natural persons, startup companies, small entities (as defined under the MSME Development Act 2006), and large entities, with differential fee structures applying to each category.

Procedural Landscape

Filing Routes for Patent Registration in india

An applicant seeking patent registration in India may proceed through one of two principal routes: the ordinary (national) route under the Patents Act 1970, or the international route under the Patent Cooperation Treaty (PCT), to which India acceded in 1998.

The Ordinary (National) Route involves filing a complete or provisional specification directly with the appropriate Patent Office. A provisional application preserves a priority date while affording the applicant twelve months to file the complete specification under Section 9(1). Filing a provisional application is strategically significant because it establishes the priority date without requiring the applicant to finalize the claims, which are only required in the complete specification.

The PCT Route permits an applicant to file a single international application with a receiving office (the Indian Patent Office is a recognised receiving office) designating multiple countries. The international application proceeds through an international search by an International Searching Authority (ISA), which produces an International Search Report and Written Opinion. India is designated as a Drawing Office and a Receiving Office under the PCT. Once the PCT application enters the national phase in India, it is treated as a national application under Chapter IV of the Patents Act, specifically under Sections 135 to 140.

Forms Required

The patent application process in India involves a structured set of prescribed forms:

Form 1 is the application for grant of a patent. It must be filed alongside the complete specification (Form 2) or, where a provisional application is filed, the provisional specification.

Form 2 contains the complete specification, which must include a title, a preamble, an optional field of invention, prior art description, objects of the invention, a detailed description, drawings (where applicable), examples (particularly in pharmaceutical and chemical applications), and the claims. The claims define the legal scope of protection and must be drafted with precision.

Form 3 is the statement and undertaking under Section 8, requiring the applicant to disclose details of corresponding foreign applications, their status, and any objections raised by foreign patent offices. This is a continuing obligation throughout the prosecution process, and non-compliance can result in revocation of a granted patent under Section 64(1)(j).

Form 5 is the declaration as to inventorship, identifying all natural persons who are the actual inventors. In cases where the applicant is not the inventor (for example, a corporate assignee), Form 5 must accompany the application.

Form 9 is used to request publication of the application, which under Section 11A can be requested before the expiry of the eighteen-month period from the priority date. Form 18 is filed to request examination, and Form 18A is used for expedited examination, available to qualifying applicants including startups, small entities, government departments, and applicants from select countries with which India has reciprocal arrangements.

Step-by-Step Prosecution Sequence

The patent prosecution process in India follows a defined sequence. First, the application is filed along with Forms 1, 2, 3, and 5, together with the prescribed fee. Second, the application is published in the Official Patent Journal after the expiry of eighteen months from the earliest priority date, unless early publication has been requested and granted under Section 11A(2). Third, the applicant files a Request for Examination (RFE) on Form 18 or Form 18A within forty-eight months from the priority date. If the RFE is not filed within this period, the application is deemed to have been withdrawn under Section 11B(4).

Fourth, the Controller assigns the application to an Examiner, who conducts a substantive examination and prepares a First Examination Report (FER). The FER is issued to the applicant and sets out all objections relating to novelty, inventive step, patentability under Section 3, clarity of claims, sufficiency of disclosure, and formal requirements. Fifth, the applicant must respond to the FER within six months from the date of issuance, extendable by three months upon request under Rule 24B. Sixth, if the objections are not resolved through written submissions, the Controller may call a hearing under Section 14, at which the applicant or an authorised patent agent may make oral arguments. Seventh, if all objections are resolved to the Controller’s satisfaction, the patent is granted and the grant is notified in the Patent Journal under Section 43.

Current Statutory Fee Schedule

The Patents (Amendment) Rules 2024 revised the fee schedule. For natural persons and startups, the filing fee for a complete specification (for up to ten pages and ten claims) stands at INR 1,600 when filed electronically. For small entities, the corresponding fee is INR 4,000. For entities other than natural persons, startups, and small entities (i.e., large entities), the fee is INR 8,000 for electronic filing.

Excess claim fees apply for each claim beyond ten, and excess page fees apply for each page of specification beyond thirty pages. The request for examination fee for a natural person or startup is INR 4,000 electronically, while for large entities it is INR 20,000. Expedited examination under Form 18A carries a premium: for natural persons and startups, INR 8,000; for large entities, INR 60,000. Annual renewal fees commence from the third year and increase progressively through to the twentieth year of the patent term. These fees are payable by natural persons, startups, and small entities at one-tenth and one-fourth of the rates applicable to large entities respectively.

Key Judicial Precedents

Patentability of Pharmaceutical Innovations

The Supreme Court of India in Novartis AG v. Union of India (2013) 6 SCC 1 delivered a landmark ruling interpreting Section 3(d) of the Patents Act 1970. The Court upheld the rejection of Novartis’s patent application for the beta-crystalline form of imatinib mesylate (Gleevec), holding that the compound did not demonstrate enhanced efficacy over the known substance and therefore did not clear the threshold established by Section 3(d). This ruling has profoundly shaped the approach of the patent office and pharmaceutical applicants to incremental innovation claims in India and has been extensively cited in subsequent examination reports.

Computer-Related Inventions

The patentability of computer-related inventions under Section 3(k) has been contested in multiple proceedings. The Guidelines for Examination of Computer Related Inventions (CRI Guidelines), revised most recently in 2017, attempt to provide a workable framework by directing examiners to assess whether the claimed invention results in a technical effect that goes beyond the normal physical interactions between the software and the hardware on which it runs. While these guidelines do not carry statutory force, they guide examination practice and are relevant to understanding the form of a response to a Section 3(k) objection.

Compulsory Licensing

In Bayer Corporation v. Union of India (2014), the Intellectual Property Appellate Board (now superseded by the High Court in its appellate jurisdiction following the Tribunals Reforms Act 2021) upheld India’s first compulsory licence, granted by the Controller to Natco Pharma Ltd for sorafenib tosylate (Nexavar). The case reinforced that the Section 84 grounds for compulsory licensing — failure to satisfy the reasonable requirements of the public, non-availability at a reasonably affordable price, and non-working of the patent in India — are strictly applied and that patent holders must actively work their patents in the Indian territory.

Patent Registration Objections Under Section 15 and Response Strategies

Section 15 of the Patents Act 1970 empowers the Controller to refuse an application or require amendments where the application or complete specification does not comply with the requirements of the Act and Rules. The most frequently encountered objections relate to the following categories.

Lack of novelty is addressed by a prior art search conducted by the examiner. The appropriate response involves distinguishing the claimed invention from each cited reference on the grounds of technical differences and demonstrating that the claimed subject matter was not anticipated by the prior art either identically or by an enabling disclosure.

Obviousness requires the applicant to demonstrate that the inventive step would not have been obvious to a person skilled in the art at the priority date, considering the common general knowledge and the cited prior art. A well-structured response will argue against hindsight reasoning and highlight the technical problem solved by the invention.

Non-patentability under Section 3 requires careful claim drafting and specification amendment to bring the claims clearly within patentable territory. For pharmaceutical inventions, responding to Section 3(d) objections requires marshalling clinical data or pharmacokinetic evidence demonstrating enhanced efficacy. For software-related inventions, the response must frame the claims in terms of a technical process or a technical effect rather than as an abstract algorithm or business method.

Insufficiency of disclosure under Section 10(4) requires the complete specification to fully and particularly describe the invention and its best method of performance. Where this objection is raised, the applicant must amend the specification to provide sufficient detail without introducing new matter that was not disclosed in the original application.

Unity of invention objections arise where the examiner considers that the application claims more than one invention. The applicant may either argue unity on the basis of a common inventive concept linking all claims, or may elect a subset of claims and file divisional applications under Section 16 for the remaining subject matter.

Patent Registration Timeline in India: From Filing to Grant

A realistic assessment of the patent registration timeline in India places the earliest possible grant at approximately three to four years from the date of filing for applications subject to ordinary examination, assuming timely responses from the applicant and no protracted hearing process. For complex applications in pharmaceutical or biotechnology sectors, or where multiple rounds of examination are required, timelines of five to seven years are common. Expedited examination under Form 18A has demonstrably shortened the timeline for eligible applicants, with grant in some cases achievable within twelve to twenty-four months of filing.

Conclusion

Patent registration in India in 2026 involves navigating a demanding multi-stage process under the Patents Act 1970 and the Patents Rules 2003 as amended. An applicant must attend to the correct choice of filing route, precise completion of the prescribed forms, timely payment of fees calibrated to the applicant’s entity category, and strategically coherent responses to examination objections. The evidentiary and doctrinal complexity of Indian patent law — particularly the unique provisions of Section 3 — requires careful specification drafting before filing and thorough preparation of response submissions at the examination stage. The judicial landscape, shaped by decisions such as Novartis v. Union of India, continues to influence the standards applied by the Controller in examination proceedings. An understanding of this framework is essential for any party seeking to secure and enforce patent rights in the Indian market.